Описание

Clinical evidence for cannabidiol in treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut is summarized. FDA-approved formulations have demonstrated significant seizure frequency reduction.

Figure 17

Chart

Source Paper

Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Seizures and Epilepsy.

Pharmaceuticals (Basel, Switzerland) (2020)

PMID: 32751761

DOI: 10.3390/ph13080174

Cite This Figure

![Figure 17: Clinical evidence for cannabidiol in treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut is summarized. FDA-approved formulations have demonstrated significant seizure frequency reduction.]()

> Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." *Pharmaceuticals (Basel, Switzerland)*, 2020. PMID: [32751761](https://pubmed.ncbi.nlm.nih.gov/32751761/)

<figure>
  <img src="" alt="Clinical evidence for cannabidiol in treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut is summarized. FDA-approved formulations have demonstrated significant seizure frequency reduction." />
  <figcaption>Figure 17. Clinical evidence for cannabidiol in treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut is summarized. FDA-approved formulations have demonstrated significant seizure frequency reduction.<br>  Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751761/">32751761</a></figcaption>
</figure>

Связанные доказательства

CBD для Бессонница

Оценка A · 103 исследований